Retatrutide, a experimental dual agonist of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) target, is showing promising data in early human trials . Recent research suggests that https://bookmarknap.com/story11918753/retatrutide-emerging-research-and-projected-medical-uses